Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00000438 · ClinicalTrials.gov registry record · Phase 4
Naltrexone Treatment for Alcoholism
A Phase 4 study, sponsored by Johns Hopkins University.
- Completed
- Registry status
- Phase 4
- Development phase
- 192
- Enrollment target
NCT00000438: Completed Phase 4 study, sponsored by Johns Hopkins University.
NCT00000438 is a Phase 4 study that has completed, run by Johns Hopkins University. The registered enrollment target is 192 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00000438, a Phase 4 study, has completed, sponsored by Johns Hopkins University.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 192 participants
- Enrollment target
Study Summary
This study will evaluate the effectiveness of the medication naltrexone (Revia) for treating alcoholism. Individuals will be inpatients for a 2 week period and provide assessments of their alcohol withdrawal symptoms, craving, and mood. Following hospital discharge, individuals will be assigned randomly to receive naltrexone daily, naltrexone twice a day or a placebo. This part of the study will last 12 weeks, with regular measurements of drinking level, craving and mood. Assessments will be conducted 6 and 12 months after the beginning of the study.
Interventions
- DRUG naltrexone (Revia)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 192 participants |
| Est. Completion | 2003-03 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00000438
The ClinicalTrials.gov registry entry for NCT00000438 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 192 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Johns Hopkins University, which has 1,448 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which naltrexone (Revia) is the first listed.
NCT00000438 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00000438 about?
NCT00000438 is a clinical study titled "Naltrexone Treatment for Alcoholism". This study will evaluate the effectiveness of the medication naltrexone (Revia) for treating alcoholism. Individuals will be inpatients for a 2 week period and provide assessments of their alcohol withdrawal symptoms, craving, and mood. Following hospital discharge, individuals will be assigned rand...
What is the current status of trial NCT00000438?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 192 participants. Estimated completion is 2003-03.
What interventions are being tested in trial NCT00000438?
The interventions under investigation include: naltrexone (Revia) (DRUG).
Who is sponsoring clinical trial NCT00000438?
This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.